Drug-related hepatotoxicity and acute liver failure

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 4, 2008, Pages 395-405

  Murray, Karen F ^a   Hadzic, Nedim ^c   Wirth, Stefan ^d   Bassett, Mikelle ^b   Kelly, Deirdre ^e  

^a Hepatobiliary Program   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

^e BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Acute liver failure; Drug toxicity; Hepatitis

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHETAMINE; AMPHOTERICIN B; AMPICILLIN; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIOBESITY AGENT; BETA LACTAM ANTIBIOTIC; CANNABIS; CEPHALOSPORIN; CLAVULANIC ACID; COTRIMOXAZOLE; ERYTHROMYCIN; ETHAMBUTOL; HALOTHANE; HERBACEOUS AGENT; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MINOCYCLINE; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; ANALGESIC AGENT;

ABDOMINAL TENDERNESS; ACUTE HEPATITIS; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; AWARENESS; BRAIN EDEMA; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FEVER; GLUCURONIDATION; HEPATIC ENCEPHALOPATHY; HEPATITIS; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPOGLYCEMIA; JAUNDICE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALAISE; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RIGOR; SCORING SYSTEM; SIDE EFFECT; SULFATION; SURVIVAL; TOXIC HEPATITIS; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; DRUG TOXICITY; FEMALE; MALE; OUTCOME ASSESSMENT; UNITED STATES;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; CHILD; DRUG TOXICITY; FEMALE; HUMANS; LIVER FAILURE, ACUTE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; UNITED STATES;

EID: 59649112470     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpg.0b013e3181709464     Document Type: Review

References (115)

1. Squires RHJ, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-8.
2. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30.
3. Avner M, Finkelstein Y, Hackham D, et al. Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Pediatr Drugs 2007;9:267-70.
4. Naranjo CA, Busto A, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239-45.
5. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9.
6. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis2006;10:207-17.
7. Mahedevan SC, McKiernan PJ, Davies P, et al. Paracetamol induced hepatotoxicity in children. Arch Dis Child 2006;91: 598-603.
8. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997;130:300-4.
9. Davern TJ, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687-94.
10. Leah WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Pediatr Gastroenterol Nutr 2005;40:575-81.
11. Bhaduri BR, Mieli-Vergani G. Fulminant hepatic failure. Semin Liv Dis 1996;16:349-55.
12. Sztajnkerycer MJ, Bond GR. Chronic acetaminophen overdosing in children; risk assessment and management. Curr Opin Pediatr2001;13:177-82.
13. Kozer E, Koren G. Management of paracetamol overdose: current controversies. Drug Safety 2001;24:503-12.
14. Lo SK,Wendon J, Mieli-Vergani G, et al. Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation. Eur J Gastroenterol Hepatol 1998;10:635-9.
15. Kenna JG, Neuberger J, Mieli-Vergani G, et al. Halothane hepatitis in children. BMJ (Clin Res Ed) 1987;294:1209-11.
16. Pratilas V, Pratila MG. Multiple halothane anesthesias in a child: a case report. Mt Sinai J Med 1978;45:480-3.
17. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996;50:573-82.
18. Current Problems. London: Committee on Safety of Medicines; 1986.
19. Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculosis chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002;72:220-6.
20. Fernández-Villar A, Sopeña B, Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis druginduced hepatotoxicity. Int J Tuberc Lung Dis 2004;8: 1499-505.
21. Ungo J, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-6.
22. Wong WM,Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology2000;31:201-6.
23. Centers for Disease Control. National Consensus Conference on Tuberculosis: preventative treatment of tuberculosis. Chest 1985; 87(Suppl 2):128-132.
24. Saukkonen JJ, Cohn DL, Jasmer RM, et al. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174: 935-52.
25. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med2003;168:443-7.
26. Larson AM, Graziani AL. Isoniazid hepatotoxicity. In: Rose BD, ed. Up to Date. Wellesley, MA: Up to Date; 2007.
27. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8.
28. Brummer DL. Isoniazid and liver disease. Ann Intern Med1971;75:643.
29. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-71.
30. Reddy KR, Schiff ER. Hepatotoxicity of antimicrobial, antifungal, and antiparasitic agents. Gastroenterol Clin North Am 1995;24: 923-36.
31. Black M, Mitchell JR, Zimmerman HJ, et al. Liver physiology and disease: isoniazid-associated hepatitis in 114 patients. Gastroenterology1975;69: 289-302.
32. SniderDE, CarasGH. Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145: 494-7.
33. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle1978;59:13-32.
34. Bass NM, Ockner RK. Drug-induced liver disease. In: Zakim D, Boyer TD (eds). Hepatopathology. Philadelphia: WB Saunders; 1996. pp. 962-1017.
35. Farrell FJ, Keeffe EB, Man KM, et al. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994;39:2255-9.
36. Cillo U, Bassanello M, Vitale A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. Transplant Int 2004;17 (11):713-6.
37. Berkowitz FE, Henderson SL, Fajman N, et al. Acute liver failure caused by isoniazid in a child receiving carbamezapine. Int J Tuberc Lung Dis 1998;2:603-6.
38. Hasagawa T, Reyes J, Nour B, et al. Successful liver transplantation for isoniazid-induced hepatic failure: a case report. Transplantation1994;57: 1274-7.
39. Mulder DJ, Mulder RJ. Drugs used in the treatment of tuberculosis and leprosy. In: Dukes MUGG (ed). Meyler's Side Effects of Drugs. Oxford, UK: Excerpta Medica; 1977. pp. 676-89.
40. Jasmer RM, Suakkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med2002;137:640-7.
41. Centers for Disease Control and Prevention ATS. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
42. Burchell B, Soars M, Monaghan G, et al. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicol Lett 2000;112:333-40.
43. Westphal JF, Brogard JM. Antibacterials and antifungal agents. In: Kaplowitz N, DeLeve LD (eds). Drug-Induced Liver Disease.New York: Marcel Dekker; 2003. pp. 471-504.
44. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-32.
45. Lucena MI, Andrade RJ, Fernandez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-6.
46. Stiegbauer KT, Smith C, Snoyer DC. The histological features of amoxicillin/clavulanic acid-induced hepatotoxicity. Hepatology1994;20: 190A.
47. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut1992;33:368-71.
48. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects: review of the literature. Eur J Med Res2001;6:139- 49.
49. Chawla A, Kahn E, Yunis EJ, et al. Rapidly progressive cholestasis: an unusual reaction to amoxicillin/clavulanic acid therapy in a child. J Pediatr 2000;136:121-3.
50. Hautekeete ML, Brenard R, Horsmans Y, et al. Liver injury related to amoxicilliclavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995;22:71-7.
51. Seaman HE, Lawrenson RA, Williams TJ, et al. The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 2001;41:852-60.
52. Hunt CM,Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994;107: 1844-7.
53. Boudreaux JP, Hayes DH, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minicycline hepatotoxicity. Transplant Proc 1993;25:1873.
54. Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 1989;298:1523-4.
55. Chamberlain MC, Schwarzenberg SJ, Akin EU, et al. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr 2006;42:232-5.
56. Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol2000;95:560-1.
57. Bhat G, Jordan J, Sokalski S, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol1998;27:74-5.
58. Kiessling S, Forrest K, Moscow J, et al. Interstitial nephritis, hepatic failure, and systemic eosinophilia after minocycline treatment. Am J Kidney Dis 2001;38:E36.
59. Carson JL, Strom BL, Duff A, et al. Acute liver disease with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med1993;119:576-83.
60. Derby LE, Jick HJ, Henry DA, et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993;158:600-2.
61. Pessayre D, Larrey D, Funck-Brentano C, et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985;16 (Suppl A):181-94.
62. Diehl AM, Latham P, Boitnott JK, et al. Cholestatic hepatitis from erythromycin ethylsuccinate. Am J Med 1984;76:931-4.
63. Dujovne CA. Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol 1978;27:1926-30.
64. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979;24:385-96.
65. Gholson CF, Warren CH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med1990;150:215-6.
66. Easton-Carter KL, HardikarW, Smith AL. Possible roxithromycininduced fulminant hepatic failure in a child. Pharmacotherapy2001;21:867-70.
67. Beard K, Belic L, Aselton P, et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol1986;26:633-7.
68. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495-9.
69. Tonder M, Nordoy A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974;9:93-6.
70. Colucci CF, Cicero ML. Hepatic necrosis and trimethoprim- sulfamethoxazole. JAMA 1975;233:952-3.
71. Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med 1985;102:722.
72. Steward DL, Johnson RC. Acute hepatitis caused by sulfamethoxazole- trimethoprim. Gastroenterology 1980;78:1323.
73. Brockner J, Boisen E. Fatal multisystemic toxicity after cotrimoxazole. Lancet 1978;1:831.
74. Zimmerman HJ, Maddrey WC. Drug-induced hepatotoxicity. In: 6th ed. Edited by Schiff L, 6th ed. Edited by Schiff ER (eds). Diseases of the Liver. Philadelphia: Lippincott; 1987.
75. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim-sulfamethoxazole. Gastroenterology 1992;102: 2148-50.
76. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology1981;80:816-9.
77. Garcia Rodriguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52.
78. Stricker BH, Block AP, Bronkhorst FB, et al. Ketoconazoleassociated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986;3:399-406.
79. Chien RN, Yang LJ, Lin PY, et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7.
80. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: prevention and management. Drug Safety1992;7:323-63.
81. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. BMJ 1987;294: 419-22.
82. Zollner E, Delport S, Bonnici F. Fatal liver failure due to ketoconazole treatment of a girl with Cushing's syndrome. J Pediatr Endocrinol 2001;14:335-8.
83. Findor JA, Sorda JA, Igartua EB, et al. Ketoconazole-induced liver damage. Medicina 1998;58:277-81.
84. Tucker RM, Haq Y, Denning DW, et al. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990;26:561-6.
85. Srebrnik A, Levtov S, Ben-Ami R, et al. Liver failure and transplantation after itraconazole treatment for toenail onychomycosis. J Eur Acad Dermatol Venereol 2005;19:205-7.
86. Gallardo-Quesada S, Luelmo-Aguilar J. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995;34:589.
87. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29: S50-4.
88. Bronstein JA, Gros P, Hernandez E, et al. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997;25:1266-7.
89. Crerar-Gilbert A, Boots R, Fraenkel D, et al. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care 1999;27:650-2.
90. Tidwell A, Swims M. Review of the newer antiepileptic drugs. Am J Manag Care 2003;9:253-76.
91. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002;22:169-83.
92. Li AM, Nelson EA, Hon EK, et al. Hepatic failure in a child with anti-epileptic hypersensitivity syndrome. J Paediatr Child Health2005;41:218-20.
93. Mitchell AA, Lacouture PG, Sheehan JE, et al. Adverse drug reactions in children leading to hospital admission. Pediatrics1988;82:24-9.
94. Powers NG, Carson SH. Idiosyncratic reactions to phenytoin. Clin Pediatr 1987;26:120-4.
95. Hadzic N, Portmann B, Davies ET, et al. Acute liver failure induced by carbamazepine. Arch Dis Child 1990;65: 315-7.
96. Bosdure E, Cano A, Roquelaure B, et al. Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure. Arch Pediatr 2004;11:1073-7.
97. Overstreet K, Costanza C, Behling C, et al. Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review. Dig Dis Sci 2002;47:1921-5.
98. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001;23:277-83.
99. Onat F, Ozkara C. Adverse effects of new antiepileptic drugs. Drugs Today 2004;40:325-42.
100. Verotti A, Greco R, Latini G, et al. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Pediatr Endocrinol Metab 2005;18:423-30.
101. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Clin Toxicol 2002;40:789-801.
102. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe hepatic hepatotoxicity. J Hepatol 1998;29:394-7.
103. Ellis AJ,Wendon JA,Williams R. Acute liver damage and ecstasy ingestion. Gut 1996;38:454-8.
104. Lange-Brock N, et al. Acute liver failure following the use of ecstasy (MDMA). J Gastroenterol 2002;40:581-6.
105. Neff GW, Reddy R, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004;41:1062-4.
106. Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal weight loss aids chaso or onshido. Ann Intern Med 2003;139:488-92.
107. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002;136:590-5.
108. Han D, Matsumaru K, Rettori D, et al. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol 2004;57: 552-62.
109. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27:391-401.
110. Aithal GP. When is a herb a drug? Eur J Gastroenterol Hepatol2005;17:391-3.
111. Seef LB, Lindsay KL, Bacon B, et al. Complementary and alternative medicine in chronic liver disease. Hepatology 2001;34:595-603.
112. Stickel F, Poschl G, Seitz HK, et al. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol2003;38:565-8.
113. Stickel F, Baumuller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003;39:62-7.
114. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002;22:195-206.
115. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplements use in patients with fulminant hepatic failure. Arch Surg 2003;138:852-8.